Saquinavir
Brand names: Invirase · Active ingredient: Saquinavir Mesylate
In short: INVIRASE in combination with ritonavir and other antiretroviral agents is indicated for the treatment of HIV infection. The twice daily administration of INVIRASE in combination with ritonavir is supported by safety data from the MaxCmin 1 study and pharmacokinetic data .
What is Saquinavir used for?
INVIRASE in combination with ritonavir and other antiretroviral agents is indicated for the treatment of HIV infection. The twice daily administration of INVIRASE in combination with ritonavir is supported by safety data from the MaxCmin 1 study and pharmacokinetic data . The efficacy of INVIRASE with ritonavir has not been compared against the efficacy of antiretroviral regimens currently considered standard of care.
In a randomized, double-blind clinical study (NV14256) in zidovudine-experienced, HIV-infected patients, INVIRASE in combination with zalcitabine was shown to be superior to either INVIRASE or zalcitabine monotherapy in decreasing the cumulative incidence of clinical disease progression to AIDS-defining events or death. Furthermore, in a randomized study (ACTG229/NV14255), patients with advanced HIV infection with history of prolonged zidovudine treatment and who were given INVIRASE 600 mg (three times daily) + zidovudine + zalcitabine experienced greater increases in CD4 cell counts as compared to those who received INVIRASE + zidovudine or zalcitabine + zidovudine. It should be noted that HIV treatment regimens that were used in these initial clinical studies of INVIRASE are no longer considered standard of care.
Saquinavir gel capsule 1000 mg twice daily coadministered with ritonavir 100 mg twice daily was studied in a heterogeneous population of 148 HIV-infected patients (MaxCmin 1 study). …
âš Boxed warning (FDA's strongest warning)
INVIRASE must be used in combination with ritonavir.
INVIRASE should not be used with lovastatin or simvastatin . Caution should be exercised if HIV protease inhibitors, including INVIRASE, are used concurrently with other HMG-CoA reductase inhibitors that are also metabolized by the CYP3A4 pathway (eg, atorvastatin). Since increased concentrations of statins can, in rare cases, cause severe adverse events such as myopathy including rhabdomyolysis, this risk may be increased when HIV protease inhibitors, including saquinavir, are used in combination with these drugs .
Concomitant use of INVIRASE and St. John's wort (hypericum perforatum) or products containing St. John's wort is not recommended. Coadministration of protease inhibitors, including INVIRASE, with St. John's wort is expected to substantially decrease protease-inhibitor concentrations and may result in sub-optimal levels of INVIRASE and lead to loss of virologic response and possible resistance to INVIRASE or to the class of protease inhibitors .
Caution should be exercised when INVIRASE and digoxin are coadministered; serum concentration of digoxin should be monitored and the dose of digoxin may need to be reduced .
A drug interaction study in healthy subjects has shown that ritonavir significantly increases plasma fluticasone propionate exposures, resulting in significantly decreased serum cortisol concentrations. Concomitant use of INVIRASE with ritonavir and fluticasone propionate is expected to produce the same effects. …
Saquinavir dosage
INVIRASE must be used in combination with ritonavir, because it significantly inhibits saquinavir's metabolism to provide increased plasma saquinavir levels.
INVIRASE 1000-mg twice daily (5 × 200-mg capsules or 2 × 500-mg tablets) in combination with ritonavir 100-mg twice daily.
Ritonavir should be taken at the same time as INVIRASE.
INVIRASE and ritonavir should be taken within 2 hours after a meal.
When administered with lopinavir/ritonavir 400/100 mg twice daily, the appropriate dose of INVIRASE is 1000 mg twice daily (with no additional ritonavir).
Clinical chemistry tests, viral load, and CD4 count should be performed prior to initiating INVIRASE therapy and at appropriate intervals thereafter.
For serious toxicities that may be associated with INVIRASE, the drug should be interrupted. INVIRASE at doses less than 1000 mg with 100 mg ritonavir twice daily are not recommended since lower doses have not shown antiviral activity. For recipients of combination therapy with INVIRASE and ritonavir, dose adjustments may be necessary. These adjustments should be based on the known toxicity profile of the individual agent and the pharmacokinetic interaction between saquinavir and the coadministered drug . Physicians should refer to the complete product information for these drugs for comprehensive dose adjustment recommendations and drug-associated adverse reactions of nucleoside analogues.
Warnings & precautions
Do not take this medicine if: INVIRASE is contraindicated in patients with clinically significant hypersensitivity (e.g. anaphylactic reaction, Stevens-Johnson syndrome) to saquinavir, saquinavir mesylate, or any of its ingredients including ritonavir.
INVIRASE/ritonavir should not be administered concurrently with rifampin, terfenadine, cisapride, astemizole, pimozide, triazolam, midazolam or ergot derivatives. Inhibition of CYP3A4 by saquinavir and ritonavir could result in elevated plasma concentrations of these drugs, potentially causing serious or life-threatening reactions, such as cardiac arrhythmias or prolonged sedation .
INVIRASE/ritonavir should not be given together with rifampin, due to the risk of severe hepatocellular toxicity if the three drugs are given together .
INVIRASE when administered with ritonavir is contraindicated in patients with severe hepatic impairment.
INVIRASE/ritonavir should not be administered concurrently with drugs listed in
Table 4
.
Drug Class | Drugs Within Class That Are Contraindicated With INVIRASE | Clinical Comment
Antiarrhythmics | Amiodarone, bepridil, flecainide, propafenone, quinidine | Potential for serious and/or threatening reactions.
Ergot Derivatives | Dihydroergotamine, ergonovine, ergotamine, methylergonovine | Potential for serious and life threatening reactions such as ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.
Antimycobacterial Agents | Rifampin | Rifampin should not be administered in patients taking ritonavir-boosted INVIRASE part of an ART regimen due to the risk of severe hepatocellular toxicity.
GI Motility Agent | Cisapride | Potential for serious and/or life threatening reactions such as cardiac arrhythmias.
Neuroleptics | Pimozide | Potential for serious and/or life threatening reactions such as cardiac arrhythmias. …
Saquinavir side effects
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
In combination with ritonavir the recommended dose of INVIRASE is 1000 mg two times daily with ritonavir 100 mg two times daily in combination with other antiretroviral agents.
Table 6
lists grade 2, 3 and 4 adverse events that occurred in ≥2% of patients receiving saquinavir soft gel capsules with ritonavir (1000/100 mg bid).
Adverse Events | Saquinavir soft gel capsules 1000 mg plus Ritonavir 100 mg bid (48 weeks)N=148n (%=n/N)
Endocrine Disorders
Diabetes mellitus/hyperglycemia | 4 (2.7)
Lipodystrophy | 8 (5.4)
Gastrointestinal Disorders
Nausea | 16 (10.8)
Vomiting | 11 (7.4)
Diarrhea | 12 (8.1)
Abdominal Pain | 9 (6.1)
Constipation | 3 (2.0)
General Disorders and Administration Site Conditions
Fatigue | 9 (6.1)
Fever | 5 (3.4)
Musculoskeletal Disorders
Back Pain | 3 (2.0)
Respiratory Disorders
Pneumonia | 8 (5.4)
Bronchitis | 4 (2.7)
Influenza | 4 (2.7)
Sinusitis | 4 (2.7)
Dermatological Disorders
Rash | 5 (3.4)
Pruritus | 5 (3.4)
Dry lips/skin | 3 (2.0)
Eczema | 3 (2.0)
Limited experience is available from three studies investigating the pharmacokinetics of the INVIRASE 500 mg film-coated tablet compared to the INVIRASE 200 mg capsule in healthy volunteers (n=140). …
About this medicine
INVIRASE brand of saquinavir mesylate is an inhibitor of the human immunodeficiency virus (HIV) protease. INVIRASE is available as light brown and green, opaque hard gelatin capsules for oral administration in a 200-mg strength (as saquinavir free base). Each capsule also contains the inactive ingredients lactose, microcrystalline cellulose, povidone K30, sodium starch glycolate, talc, and magnesium stearate. Each capsule shell contains gelatin and water with the following dye systems: red iron oxide, yellow iron oxide, black iron oxide, FD&C Blue #2, and titanium dioxide.
INVIRASE is also available as a light orange to greyish- or brownish-orange, oval cylindrical, biconvex film-coated tablet for oral administration in a 500-mg strength (as saquinavir free base). Each tablet also contains the inactive ingredients lactose, microcrystalline cellulose, povidone K30, croscarmellose sodium, and magnesium stearate. Each film coat contains hypromellose, titanium dioxide, talc, iron oxide yellow, iron oxide red, and triacetin. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID b8b53129-06ab-4143-b9b7-7675e49a52ef. Read the full official label on DailyMed.